Arthrogen Overview

  • Year Founded
  • 2005

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 15

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $621K

Arthrogen General Information

Description

Developer of a local gene therapy intended for different indications, using viral-mediated gene transfer. The company specializes in the development of viral gene therapy vectors, in particular, adeno-associated virus (AAV-) based therapeutics, enabling health professionals to cure inflammatory diseases.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Meibergdreef 45
  • 1105 BA Amsterdam
  • Netherlands
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • Meibergdreef 45
  • 1105 BA Amsterdam
  • Netherlands

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Arthrogen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 17-Oct-2019 $621K Completed Generating Revenue
2. Early Stage VC Completed Generating Revenue
1. Joint Venture 01-Jan-2005 Completed Generating Revenue
To view Arthrogen’s complete valuation and funding history, request access »

Arthrogen Patents

Arthrogen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2019141765-A1 A modified raav capsid protein for gene therapy Inactive 17-Jan-2018
AU-2015330092-A1 Aav-based gene therapy Inactive 06-Oct-2014
EP-3204503-A1 Aav-based gene therapy Inactive 06-Oct-2014
US-20170304466-A1 Aav-based gene therapy Inactive 06-Oct-2014
WO-2016055437-A1 Aav-based gene therapy Inactive 06-Oct-2014 A61K48/0083
To view Arthrogen’s complete patent history, request access »

Arthrogen Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Arthrogen Former Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Amsterdam UMC Ventures Holding Venture Capital Minority
Dubai Bone & Joint Center Corporation Majority
The Academic Medical Center Corporation Majority
UvA Ventures Holding Venture Capital Minority
To view Arthrogen’s complete investors history, request access »

Arthrogen FAQs

  • When was Arthrogen founded?

    Arthrogen was founded in 2005.

  • Where is Arthrogen headquartered?

    Arthrogen is headquartered in Amsterdam, Netherlands.

  • What is the size of Arthrogen?

    Arthrogen has 15 total employees.

  • What industry is Arthrogen in?

    Arthrogen’s primary industry is Drug Discovery.

  • Is Arthrogen a private or public company?

    Arthrogen is a Private company.

  • What is the current valuation of Arthrogen?

    The current valuation of Arthrogen is .

  • What is Arthrogen’s current revenue?

    The current revenue for Arthrogen is .

  • Who are Arthrogen’s investors?

    Amsterdam UMC Ventures Holding, Dubai Bone & Joint Center, The Academic Medical Center, and UvA Ventures Holding have invested in Arthrogen.

  • When was Arthrogen acquired?

    Arthrogen was acquired on 17-Oct-2019.

  • Who acquired Arthrogen?

    Arthrogen was acquired by MeiraGTx.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process